USC Norris Comprehensive Cancer Center and Hospital
Welcome,         Profile    Billing    Logout  
 6 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ballas, Leslie
NRG-GU013, NCT05946213: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Recruiting
3
1209
Canada, US
External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
03/36
03/41
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
NRG PROMETHEAN, NCT05053152: Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer

Recruiting
2
260
Canada, US
Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
02/29
02/30
NCT06417190: Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Not yet recruiting
2
20
US
Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Leslie Ballas
Muscle-Invasive Bladder Carcinoma, Tumor
09/30
09/30
NCT02446366: Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

Active, not recruiting
1
24
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SBRT
University of Southern California, National Cancer Institute (NCI)
Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Adenocarcinoma
02/20
02/23
NCT05887167: Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects with Relapsed/Refractory Hematological Malignancies

Recruiting
1
20
US
autologous hematopoietic stem cells added to planned CAR T
Joshua Sasine, MD, PhD
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma
12/25
12/26
NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Recruiting
N/A
100
US
Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
University of Southern California, National Cancer Institute (NCI)
Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
03/25
03/26

Download Options